NEW YORK (GenomeWeb) – Swedish diagnostic developer Immunovia said today that it has established a US subsidiary in Boston. The facility will house a CLIA reference lab and commercialization operations for the firm, which is preparing to launch its first test — a liquid biopsy assay for pancreatic cancer called Immray PanCan-d — in the first half of 2018.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

NPR reports that with medical data being big business, some companies want to get patients involved.

The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.

In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.

Nov
05
Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.